Johnson & Johnson's Coronavirus Vaccine Candidate Efficacious in Pre-Clinical Studies; Human Testing Has Begun
The company aims to start a phase 3 clinical trial for Ad26.COV2-S in September.
Full Article
Johnson & Johnson's Coronavirus Vaccine Candidate Efficacious in Pre-Clinical Studies; Human Testing Has Begun
Motley Fool
0 shares
1 views
You might like
Related news coverage
How Do Vaccine Trials Get Their Volunteer Testers?
Newsy
Watch VideoJennifer Haller of Seattle is proud to be the first American to ever get a potential COVID-19..
Advertisement
More coverage
NA Proactive news snapshot: Humanigen, NetCents Technology, Talon Metals, Aftermath Silver, OTC Markets Group, Karora Resources UPDATE …
Proactive Investors
Humanigen Inc (OTCQB:HGEN) said Monday that its lead drug candidate lenzilumab was selected for use in the National Institute of..
-
Which Canadians get the COVID-19 vaccine first? Experts have to decide
National Post
-
US signs contract with Pfizer for COVID-19 vaccine doses
SeattlePI.com
-
Support grows for deliberately exposing vaccine trial subjects to COVID-19, with Oxford team leading the way
National Post
-
First COVID-19 vaccine tested in US poised for final testing
Mid-Day